



COMMITTEE ON RULES

I Mina'trentai Tres na Liheslaturan Guåhan • The 33rd Guam Legislature

155 Hesler Place, Hagåtña, Guam 96910 • www.guamlegislature.com

E-mail: roryforguam@gmail.com • Tel: (671)472-7679 • Fax: (671)472-3547

Senator
Rory J. Respicio
CHAIRPERSON
MAJORITY LEADER

June 9, 2016

Senator
Thomas C. Ada
VICE CHAIRPERSON
ASSISTANT MAJORITY LEADER

Memorandum

Speaker
Judith T.P. Won Pat, Ed.D.
Member

To: **Rennae Meno**
Clerk of the Legislature

Vice-Speaker
Benjamin J.F. Cruz
Member

From: **Senator Thomas C. Ada** *[Signature]*
Acting Chairperson of the Committee on Rules

Legislative Secretary
Tina Rose Muna Barnes
Member

Subject: **Fiscal Notes and Fiscal Note Waiver**

Senator
Dennis G. Rodriguez, Jr.
Member

Hafa Adai!

Attached please find the fiscal notes and fiscal note waiver for the bill numbers listed below. Please note that the fiscal notes and fiscal note waiver are issued on the bills as introduced.

FISCAL NOTES:

Senator
Frank Blas Aguon, Jr.
Member

- Bill No. 298-33(COR)
- Bill No. 317-33(COR)
- Bill No. 322-33(COR)
- Bill No. 324-33(COR)
- Bill No. 329-33(COR)

Senator
Michael F.Q. San Nicolas
Member

FISCAL NOTE WAIVER:

Senator
Nerissa Bretania Underwood
Member

- Bill No. 316-33(COR)

V. Anthony Ada
MINORITY LEADER

Please forward the same to MIS for posting on our website. Please contact our office should you have any questions regarding this matter.

Mary C. Torres
MINORITY MEMBER

Si Yu'os ma'åse'!

2016 JUN 10 AM 10:45 [Signature]



BUREAU OF BUDGET & MANAGEMENT RESEARCH

OFFICE OF THE GOVERNOR

Post Office Box 2950, Hagåtña Guam 96932

EDDIE BAZA CALVO
GOVERNOR

RAY TENORIO
LIEUTENANT GOVERNOR

JOSE S. CALVO
DIRECTOR


LESTER L. CARLSON, JR.
DEPUTY DIRECTOR

JUN 03 2016

The Bureau requests that Bill No(s). 316-33 (COR) be granted a waiver pursuant to Public Law 12-229 as amended for the following reason(s):

Legislative Bill No. 316-33 seeks to provide the opportunity to those patients with advance illness access to experimental treatment of investigational drug, biological product or device that have not been approved for general use by the United States Food and Drug Administration. This proposed legislation also provides the administrative framework for determining an eligible patient, defining the criteria for an investigational drug, biological product or device, and identifying party liability with respect to service liabilities and costs. With such use, provisions within this proposed legislation provide professional protection to healthcare providers who recommend or provide treatment to terminally-ill patients. Such experimental treatments and applications shall not be prevented by public officials.

There are no new revenue streams noted in this Bill; nor are appropriations made to fund such legislative act. Therefore Legislative Bill No. 316-33 is administratively procedural.


JOSE S. CALVO